Anavex Life Sciences (AVXL) EBT (2016 - 2025)

Anavex Life Sciences (AVXL) has 10 years of EBT data on file, last reported at -$2.6 billion in Q4 2025.

• For the quarter ending Q4 2025, EBT fell 2989.98% year-over-year to -$2.6 billion; the trailing twelve-month figure through Dec 2025 stood at -$42.4 billion (down 36082.39% YoY), and the FY2025 full-year result was -$39.8 billion, down 92377.13% from the prior year.
• EBT climbed to -$2.6 billion in Q4 2025, from -$39.7 billion in the prior quarter.
• In the past five years, EBT ranged from a high of -$8.2 million in Q1 2021 to a low of -$39.7 billion in Q3 2025.
• A 5-year average of -$2.1 billion and a median of -$12.0 million in 2022 frame the typical range for EBT.
• Across the five-year window, EBT surged 34.29% in 2023 and slumped 338170.2% in 2025, its largest moves.
• Tracing AVXL's EBT over 5 years: stood at -$10.9 million in 2021, then declined by 19.72% to -$13.0 million in 2022, then surged by 34.29% to -$8.5 million in 2023, then tumbled by 868.72% to -$82.7 million in 2024, then sank by 2989.98% to -$2.6 billion in 2025.
• Business Quant data shows AVXL's EBT at -$2.6 billion in Q4 2025, -$39.7 billion in Q3 2025, and -$60.3 million in Q2 2025.